Celgene to Buy Juno for $9 Billion, Signaling Cancer Aspirations


Celgene Corp. said on Monday it would pay about $9 billion in cash to acquire the rest of Juno Therapeutics Inc. and gain access to Juno's experimental gene therapy to treat cancer. The $9 billion represents an offer $87 per share to Juno's shareholders and the deal, agreed by both boards, is expected to close in the first quarter of 2018.



from Biotech News